Alliance for Pandemic Preparedness

January 29, 2021

The effectiveness of the first dose of BNT162 b 2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization real-world evidence

Category:

Topic:

Keywords (Tags): ,

[Pre-print, not peer-reviewed] The first dose of the BNT162b2 mRNA COVID-19 vaccine (Pfizer–BioNTech) is associated with an approximately 51% reduction in the incidence of PCR-confirmed SARS-CoV-2 infections at 13 to 24 days after immunization compared to the rate during the first 12 days. These findings are based on a retrospective cohort study in Israel (December 19 to January 15). Similar levels of effectiveness were found across age groups, sex, as well as among individuals residing in Arab or ultra-orthodox Jewish communities that have experienced an increased COVID-19 risk.

Chodcik et al. (Jan 29, 2021). The effectiveness of the first dose of BNT162 b 2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization real-world evidence. Pre-print downloaded Jan 29 from https://doi.org/10.1101/2021.01.27.21250612